| Literature DB >> 30410426 |
Khadijeh Zare1, Milad Shademan1, Mohammad M Ghahramani Seno1,2, Hesam Dehghani1,2,3.
Abstract
BACKGROUND: With the increasing discovery of long noncoding RNAs (lncRNAs), the application of functional techniques that could have very specific, efficient, and robust effects and readouts is necessary. Here, we have applied and analyzed three gene knockout (KO) strategies to ablate the CCAT1 gene in different colorectal adenocarcinoma cell lines. We refer to these strategies as "CRISPR excision", "CRISPR HDR", and "CRISPR du-HITI".Entities:
Keywords: CCAT1; CRISPR/Cas9; Cancer cell; Knockout; Long noncoding RNA
Year: 2018 PMID: 30410426 PMCID: PMC6211572 DOI: 10.1186/s12575-018-0086-5
Source DB: PubMed Journal: Biol Proced Online ISSN: 1480-9222 Impact factor: 3.244
Fig. 1CRISPR/Cas9 knockout strategies for ablation of CCAT1 lncRNA gene. a “CRISPR excision”. To delete a genomic fragment (here, exon 1) two sgRNAs are targetted to either side of the fragment. Non- homologous end joining of the two remaining parts of genomic DNA after Cas9-induced double-strand breaks (DSBs) results in the deletion of the genomic fragment. b “CRISPR HDR”. In this strategy, using one sgRNA and Cas9-induced DSB in one region is followed by homology-directed repair using a reporter (CMV-PuroR-IRES2-EGFP) plus polyadenylation signal fragment (originated from a donor vector with homology arms). In this case, any transcript initiated from the first or second exon is confronted by a premature transcription termination. c “CRISPR du-HITI”. This strategy uses two donor vectors without homology arms. Two vectors containing sgRNA+PAM are used as donors, one with EGFP expression cassette, and the other with a PuroR expression cassette. Use of two sgRNAs directs the Cas9 protein towards the two either end of exon 1 at both alleles. Endonuclease function of Cas9 results into deletion of a genomic fragment (here, exon 1) from each allele, and linearization of two donor vectors. Selection of cells for their green color and their resistance to puromycin dihydrochloride results into cells with their both alleles targetted and knocked out
Fig. 2Confirmation of the CCAT1 knockouts and qPCR analysis. a CCAT1 wild-type locus and its knockout alleles by “CRISPR excision”, “CRISPR du-HITI”, and “CRISPR HDR”. Location of sgRNA binding sites (sgRNA b. s.), primers to perform PCR analysis (Table 4), and inserted fragments are shown. “CRISPR excision” of exon I (Ex. I) is confirmed by a 409 bp PCR fragment using two primers at either side of exon I. “CRISPR du-HITI” is confirmed by a PCR product of 495 bp using a primer in the insert and the other in the flanking region. The insert used for “CRISPR du-HITI” could express EGFP (bright green) or puroR (light blue) under CAG promoter. In this strategy when two alleles are targetted simultaneously, then the cells show both green fluorescence and resistance to puromycin dihydrochloride. “CRISPR HDR” was performed on exon II using an insert containing DSred (red in color), CMV, puroR, IRES, GFP, PA (poly adenylation signal, purple in color). In “CRISPR HDR” strategy cells with only one targetted allele could show both green fluorescence and resistance to puromycin dihydrochloride. PCR analysis using a primer in the insert and the other in the flanking region results in a 1627 bp product (Table 4). b Gel electrophoresis of PCR fragments for wild-type (w.t.) (a), CRISPR excised (b; clone # 20), “CRISPR du-HITI” knockout (c; clone # 27), and “CRISPR HDR” alleles (e; clone # 2i) according to the maps in panel A. Lane d is DNA size marker. c CCAT1 transcript relative to β-actin levels in wild-type and “CRISPR excision” knockout HT-29 colon adenocarcinoma cells. d CCAT1 transcript relative to β-actin levels in wild-type and “CRISPR HDR” knockout HCT-116 colon adenocarcinoma cells. e CCAT1 transcript relative to β-actin levels in wild-type and “CRISPR du-HITI” knockout SW-480 colon adenocarcinoma cells. In panels, C, D, and E the absolute copy number for CCAT1 and β-actin transcripts were quantified based on the related standard curves, and for three series of cell line cDNAs, the quantity of the CCAT1 transcript divided by the quantity of the β-actin was plotted. The statistical differences between the wild-type and knockout cell lines are analyzed by Mann-Whitney U test
Oligonucleotides used in this study
| Gene | Sequence (5′ to 3′) | Product (bP) | Application |
|---|---|---|---|
| CCAT1 (NR_108049.1) | F: CTGACAACATCGACTTTG | 108 | qPCR |
| F: CGATCGttctgttttcaatggggatt | 546 | Cloning of left homology arm | |
| F: CTAGTCCCgcatcacagctactgtcaaccc | 832 | Cloning of right homology arm | |
| Forward-1: CACATGGCTCCCATCACACTA | 1298 (w.t.) 409 (ko) | PCR confirmation of CRISPR Excision knockout allele | |
| Forward-2: CACGCAGATCACATGACCCT | 1627 (ko) | PCR confirmation of CRISPR HDR knockout allele | |
| Forward-2: CACGCAGATCACATGACCCT | 843 (w.t.) | PCR confirmation of CRISPR HDR wild-type allele | |
| Forward-3: CGGGCCATTTACCGTAAG | 495 (ko) | PCR confirmation of CRISPR du-HITI knockout allele | |
| F: CACCGaatcggagtccaaagccatt | – | sgRNA (downstream of Exon 1) | |
| F: CACCGataatggaggggatttacgt | – | sgRNA (upstream of Exon 1) | |
| F: CACCGctgttatccgcagctccatc | – | sgRNA (Exon 2) | |
| F: CACCGaatggctttggactccgatttgg | – | sgRNA bait (+PAM) (downstream of Exon 1) | |
| b-Actin | F: TGCAGAAGGAGATCACTG | 141 | qPCR |
Enriched gene ontology terms in the CCAT1 wild-type versus CCAT1 knockout transcriptomes derived from differentially expressed genes (in the category of molecular function)
| ID | Term | Gene Count | |
|---|---|---|---|
| GO:0004867 | serine-type endopeptidase inhibitor activity | 9 | 2.50E-04 |
| GO:0016491 | oxidoreductase activity | 12 | 6.60E-04 |
| GO:0005515 | protein binding | 171 | 9.60E-03 |
| GO:0008236 | serine-type peptidase activity | 5 | 2.30E-02 |
| GO:0004879 | RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding | 4 | 2.30E-02 |
| GO:0004252 | serine-type endopeptidase activity | 10 | 3.10E-02 |
| GO:0015485 | cholesterol binding | 4 | 3.30E-02 |
| GO:0004029 | aldehyde dehydrogenase (NAD) activity | 3 | 3.30E-02 |
| GO:0032810 | sterol response element binding | 2 | 3.40E-02 |
| GO:0003727 | single-stranded RNA binding | 4 | 3.70E-02 |
| GO:0016620 | oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor | 3 | 4.10E-02 |
| GO:0004715 | non-membrane spanning protein tyrosine kinase activity | 4 | 4.40E-02 |
| GO:0005506 | iron ion binding | 7 | 4.70E-02 |
| GO:0003779 | actin binding | 10 | 4.90E-02 |
aOnly GO terms with p value of less than 0.05 are shown
Enriched gene ontology terms in the CCAT1 wild-type versus CCAT1 knockout transcriptomes derived from differentially expressed genes (in the category of biological process)
| ID | Term | Gene Count | |
|---|---|---|---|
| GO:0042493 | response to drug | 17 | 4.50E-05 |
| GO:0055114 | oxidation-reduction process | 24 | 1.30E-04 |
| GO:0031295 | T cell costimulation | 7 | 1.80E-03 |
| GO:0008283 | cell proliferation | 15 | 3.00E-03 |
| GO:0030522 | intracellular receptor signaling pathway | 5 | 3.40E-03 |
| GO:0010951 | negative regulation of endopeptidase activity | 8 | 3.90E-03 |
| GO:0090090 | negative regulation of canonical Wnt signaling pathway | 9 | 5.60E-03 |
| GO:0008285 | negative regulation of cell proliferation | 15 | 6.00E-03 |
| GO:0006805 | xenobiotic metabolic process | 6 | 9.20E-03 |
| GO:0051897 | positive regulation of protein kinase B signaling | 6 | 1.20E-02 |
| GO:0030449 | regulation of complement activation | 4 | 1.30E-02 |
| GO:0006081 | cellular aldehyde metabolic process | 3 | 1.30E-02 |
| GO:0048013 | ephrin receptor signaling pathway | 6 | 1.40E-02 |
| GO:0001822 | kidney development | 6 | 1.40E-02 |
| GO:0007612 | learning | 5 | 1.40E-02 |
| GO:0032091 | negative regulation of protein binding | 5 | 1.40E-02 |
| GO:0046685 | response to arsenic-containing substance | 3 | 1.90E-02 |
| GO:0007568 | aging | 8 | 1.90E-02 |
| GO:0060337 | type I interferon signaling pathway | 5 | 2.10E-02 |
| GO:0042632 | cholesterol homeostasis | 5 | 2.10E-02 |
| GO:0043524 | negative regulation of neuron apoptotic process | 7 | 2.20E-02 |
| GO:0006954 | inflammatory response | 13 | 2.30E-02 |
| GO:0016477 | cell migration | 8 | 2.40E-02 |
| GO:0006636 | unsaturated fatty acid biosynthetic process | 3 | 2.50E-02 |
| GO:0032570 | response to progesterone | 4 | 2.60E-02 |
| GO:0038083 | peptidyl-tyrosine autophosphorylation | 4 | 2.80E-02 |
| GO:0008360 | regulation of cell shape | 7 | 2.80E-02 |
| GO:0032526 | response to retinoic acid | 4 | 3.00E-02 |
| GO:0002223 | stimulatory C-type lectin receptor signaling pathway | 6 | 3.00E-02 |
| GO:0003057 | regulation of the force of heart contraction by chemical signal | 2 | 3.30E-02 |
| GO:0045785 | positive regulation of cell adhesion | 4 | 3.30E-02 |
| GO:0042127 | regulation of cell proliferation | 8 | 3.40E-02 |
| GO:0031668 | cellular response to extracellular stimulus | 3 | 3.50E-02 |
| GO:0009615 | response to virus | 6 | 3.50E-02 |
| GO:0030325 | adrenal gland development | 3 | 3.80E-02 |
| GO:0071222 | cellular response to lipopolysaccharide | 6 | 3.90E-02 |
| GO:0030154 | cell differentiation | 14 | 4.30E-02 |
| GO:0014070 | response to organic cyclic compound | 4 | 4.70E-02 |
| GO:0070668 | positive regulation of mast cell proliferation | 2 | 4.90E-02 |
| GO:0060675 | ureteric bud morphogenesis | 2 | 4.90E-02 |
| GO:0006991 | response to sterol depletion | 2 | 4.90E-02 |
aOnly GO terms with p value of less than 0.05 are shown
Enriched gene ontology terms in the CCAT1 wild-type versus CCAT1 knockout transcriptomes derived from differentially expressed genes (in the category of cellular component)
| ID | Term | Gene Count | |
|---|---|---|---|
| GO:0070062 | extracellular exosome | 78 | 4.50E-06 |
| GO:0005615 | extracellular space | 42 | 1.30E-04 |
| GO:0005829 | cytosol | 78 | 1.10E-03 |
| GO:0005576 | extracellular region | 42 | 4.20E-03 |
| GO:0031234 | extrinsic component of cytoplasmic side of plasma membrane | 6 | 5.50E-03 |
| GO:0002102 | podosome | 4 | 7.20E-03 |
| GO:0005856 | cytoskeleton | 14 | 9.80E-03 |
| GO:0030687 | preribosome, large subunit precursor | 4 | 1.20E-02 |
| GO:0031528 | microvillus membrane | 3 | 3.90E-02 |
| GO:0005886 | plasma membrane | 83 | 4.10E-02 |
| GO:0072562 | blood microparticle | 7 | 4.20E-02 |
| GO:0034666 | integrin alpha2-beta1 complex | 2 | 4.90E-02 |
aOnly GO terms with p value of less than 0.05 are shown
Fig. 3CCAT1 knockout cells lose the capacity for anchorage-independent growth. a Representative images of soft agar colony formation assay for wild-type and CCAT1 KO cell lines and evaluation of colony count and colony area in these lines. b MTT assay in HT-29, HCT-116, and SW-480 wild-type and CCAT1 KO cell lines performed 2 h and 24 h after seeding. The statistical differences between the wild-type and knockout cell lines are analyzed by Mann-Whitney test. The scale bars in panel A denote 200 μm
DNA constructs used in this study
| Construct | Features | Application |
|---|---|---|
| pX459_2 | hU6 promoter- sgRNA (downstream of CCAT1 Exon 1)-sgRNA scaffold-CAG promoter-Cas9-T2A- PuroR-bGH polyA | CRISPR Excision |
| pX459_3 | hU6 promoter- sgRNA (upstream of CCAT1 Exon 1)-sgRNA scaffold-CAG promoter-Cas9-T2A- PuroR-bGH polyA | CRISPR Excision |
| pX459_13 | hU6 promoter- sgRNA (CCAT1 Exon 2)-sgRNA scaffold-CAG promoter-Cas9-T2A- PuroR-bGH polyA | CRISPR HDR |
| pHD_4317_CCAT1 E2 HAs | Exon 2 LHA-DsRed2-HSV TK polyA-CMV promoter –PuroR-IRES2-EGFP-SV40 polyA-Exon 2 RHA | CRISPR HDR |
| pX460_11 | hU6 promoter-sgRNA (downstream of CCAT1 Exon 1) plus PAM-sgRNA scaffold-CAG promoter-EGFP-bGH polyA | CRISPR du-HITI |
| pX461_11 | hU6 promoter-sgRNA (downstream of CCAT1 Exon 1) plus PAM-sgRNA scaffold-CAG promoter-PuroR-bGH polyA | CRISPR du-HITI |
hU6 human U6 promoter, sgRNA single guide RNA, PuroR puromycin N-acetyltransferase, bGH bovine growth hormone polyadenylation signal, SV40 polyA SV40 polyadenylation signal, IRES internal ribosome entry site